Canadian pharma firm Valeant will get to takeover North Carolina’s Salix after an improved offer was accepted.
Canadian pharma firm Valeant will get to takeover North Carolina’s Salix after an improved offer was accepted. Irish firm Endo had made a better offer than Valeant’s original $158 per share, putting the deal at risk. Valeant’s new offer of $173 per share was too rich for Endo to compete with. The deal values Salix at U$15.8 billion including debt.
